Target Name: CXADR
NCBI ID: G1525
Review Report on CXADR Target / Biomarker Content of Review Report on CXADR Target / Biomarker
CXADR
Other Name(s): CXAR_HUMAN | coxsackievirus B-adenovirus receptor | CXADR Ig-like cell adhesion molecule | HCAR | Coxsackievirus and adenovirus receptor (isoform 1) | CVB3-binding protein | coxsackie virus and adenovirus receptor | 46 kD coxsackievirus and adenovirus receptor (CAR) protein | CXADR Ig-like cell adhesion molecule, transcript variant 1 | CAR4/6 | hCAR | HCVADR | CAR | Coxsackievirus and adenovirus receptor | Coxsackievirus B-adenovirus receptor | CXADR variant 1

CXADR: A Target for Multi-GPCR Modulation

CXADR (CXAR\\_HUMAN), also known as human cross-talk adenosine decoy receptor, is a protein that is expressed in various tissues throughout the body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling.

CXADR is highly expressed in the brain and is involved in a wide range of physiological processes, including pain perception, anxiety, and mood regulation. It is also involved in the regulation of inflammation, which is a critical aspect of the immune system.

One of the unique features of CXADR is its ability to interact with multiple GPCR signaling pathways. This makes it an attractive target for drug development, as it allows for the development of compounds that can modulate its activity without disrupting its function in multiple downstream signaling pathways.

CXADR is also known as the adenosine receptor A2A, which is a member of the A2A receptor subfamily. The A2A receptor subfamily is a family of GPCR that is involved in the regulation of pain perception, anxiety, and other physiological processes.

The A2A receptor subfamily includes several different genes, including A2A, A2B, A2C, and A2D. These genes are involved in the regulation of different physiological processes, including pain perception, anxiety, and the regulation of inflammation.

CXADR is a splice variant gene that is encoded by the A2A receptor subfamily gene. It is a 14kDa protein that is expressed in various tissues throughout the body, including the brain, heart, and pancreas.

CXADR is involved in a wide range of physiological processes, including pain perception, anxiety, and mood regulation. It is also involved in the regulation of inflammation, which is a critical aspect of the immune system.

One of the unique features of CXADR is its ability to interact with multiple GPCR signaling pathways. This makes it an attractive target for drug development, as it allows for the development of compounds that can modulate its activity without disrupt

Protein Name: CXADR Ig-like Cell Adhesion Molecule

Functions: Component of the epithelial apical junction complex that may function as a homophilic cell adhesion molecule and is essential for tight junction integrity. Also involved in transepithelial migration of leukocytes through adhesive interactions with JAML a transmembrane protein of the plasma membrane of leukocytes. The interaction between both receptors also mediates the activation of gamma-delta T-cells, a subpopulation of T-cells residing in epithelia and involved in tissue homeostasis and repair. Upon epithelial CXADR-binding, JAML induces downstream cell signaling events in gamma-delta T-cells through PI3-kinase and MAP kinases. It results in proliferation and production of cytokines and growth factors by T-cells that in turn stimulate epithelial tissues repair

The "CXADR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXADR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CXADRP1 | CXADRP2 | CXADRP3 | CXCL1 | CXCL10 | CXCL11 | CXCL12 | CXCL13 | CXCL14 | CXCL16 | CXCL17 | CXCL2 | CXCL3 | CXCL5 | CXCL6 | CXCL8 | CXCL9 | CXCR1 | CXCR2 | CXCR2P1 | CXCR3 | CXCR4 | CXCR5 | CXCR6 | CXorf30 | CXorf38 | CXorf49 | CXorf49B | CXorf51A | CXorf51B | CXorf58 | CXorf65 | CXorf66 | CXXC1 | CXXC1P1 | CXXC4 | CXXC4-AS1 | CXXC5 | CYB561 | CYB561A3 | CYB561D1 | CYB561D2 | CYB5A | CYB5B | CYB5D1 | CYB5D2 | CYB5R1 | CYB5R2 | CYB5R3 | CYB5R4 | CYB5RL | CYBA | CYBB | CYBC1 | CYBRD1 | CYC1 | Cyclin | Cyclin A | Cyclin B | Cyclin D | Cyclin D2-CDK4 complex | Cyclin-dependent kinase | Cyclin-dependent kinase inhibitor | Cyclooxygenase (COX) | Cyclophilins | CYCS | CYCSP25 | CYCSP34 | CYCSP38 | CYCSP51 | CYCSP52 | CYCSP53 | CYCSP55 | CYFIP1 | CYFIP2 | CYGB | CYLC1 | CYLC2 | CYLD | CYLD-AS1 | CYMP | CYP11A1 | CYP11B1 | CYP11B2 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1A2 | CYP1B1 | CYP1B1-AS1 | CYP20A1 | CYP21A1P | CYP21A2 | CYP24A1 | CYP26A1 | CYP26B1 | CYP26C1 | CYP27A1 | CYP27B1 | CYP27C1